Alignment Healthcare (NASDAQ:ALHC) Releases Earnings Results, Beats Expectations By $0.03 EPS

Alignment Healthcare (NASDAQ:ALHC) announced its earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03, FiscalAI reports. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.22 billion. During the same quarter in the previous year, the business posted ($0.05) earnings per share. Alignment Healthcare’s quarterly revenue was up 33.3% on a year-over-year basis.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Membership grew ~31% YoY to 284,800, revenue rose 33% to $1.2B and Adjusted EBITDA increased 88% to $38M — results beat guidance and management raised full‑year revenue and profitability ranges.
• Management highlighted material operational progress — claims auto‑adjudication improved from <15% to >60% YTD — and is investing in AI, contract automation and talent to drive further scale and margin expansion.
• A CMS rule change exposed an internal workflow error that caused the company to pay acute rates instead of observation in January (about a $2M impact that cannot be clawed back); the process was corrected by end of February.
• Full‑year and Q2 guidance incorporate higher inpatient admissions per 1,000 driven by intentional growth in higher‑acuity D‑SNP/LIS/dual members and a cautious risk‑adjustment stance for new members, with potential upside from later CMS “sweeps.”

Alignment Healthcare Price Performance

ALHC traded up $0.82 on Thursday, hitting $22.54. 5,274,110 shares of the stock were exchanged, compared to its average volume of 3,307,599. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of -2,251.75, a PEG ratio of 4.46 and a beta of 1.20. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. Alignment Healthcare has a 12 month low of $11.63 and a 12 month high of $23.87. The business has a 50-day moving average of $19.38 and a two-hundred day moving average of $19.42.

Insider Activity

In related news, CEO John E. Kao sold 250,000 shares of the stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $21.01, for a total transaction of $5,252,500.00. Following the sale, the chief executive officer owned 2,104,641 shares in the company, valued at approximately $44,218,507.41. This trade represents a 10.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 36,749 shares of Alignment Healthcare stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total transaction of $655,602.16. Following the completion of the transaction, the president directly owned 1,058,813 shares in the company, valued at $18,889,223.92. This trade represents a 3.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 1,474,097 shares of company stock worth $28,679,550. Insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Alignment Healthcare

A number of large investors have recently modified their holdings of the business. Summit Securities Group LLC bought a new position in shares of Alignment Healthcare in the 4th quarter valued at $26,000. Parallel Advisors LLC grew its position in Alignment Healthcare by 87.7% in the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after acquiring an additional 773 shares during the last quarter. Larson Financial Group LLC acquired a new position in Alignment Healthcare during the third quarter worth about $33,000. Wilmington Savings Fund Society FSB acquired a new position in Alignment Healthcare during the third quarter worth about $53,000. Finally, Wexford Capital LP bought a new position in shares of Alignment Healthcare in the third quarter worth about $164,000. Institutional investors and hedge funds own 86.19% of the company’s stock.

More Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q1 2026 results beat estimates — EPS $0.05 vs. $0.02 expected and revenue $1.24B vs. $1.22B consensus; management highlighted disciplined growth and margin expansion, a direct catalyst for the stock move. Q1 Press Release
• Positive Sentiment: Zacks upgraded ALHC from “hold” to “strong-buy,” which can attract momentum and buy-side interest following the earnings beat. Zacks Upgrade
• Positive Sentiment: Technical analysts point to a bullish pennant and breakout potential into prior highs, offering a short-term technical tailwind for traders. FXEmpire Technical Note
• Neutral Sentiment: Management updated Q2 2026 revenue guidance to ~$1.3B and FY2026 revenue guidance to ~$5.2B — both essentially in line with consensus — but EPS guidance was not provided in the update, leaving some earnings visibility unresolved. GlobeNewswire Release
• Neutral Sentiment: Pre-earnings coverage and sector pieces provided context but no new fundamentals; useful for framing but unlikely to move the stock materially beyond the results and upgrade. Earnings Preview
• Negative Sentiment: Despite the beat, the company remains close to break-even profitability: reported a slightly negative net margin (-0.02%) and negative return on equity (~-0.49%) in the quarter, which could cap upside if sustainable margin improvement is uncertain. Q1 Press Release (details)

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Wall Street Zen cut shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Zacks Research raised shares of Alignment Healthcare from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research report on Monday, April 20th. TD Cowen boosted their price target on Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, KeyCorp reissued an “overweight” rating and set a $28.00 price target on shares of Alignment Healthcare in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alignment Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.